Top

International Journal of Clinical Oncology

Published in:

01-04-2015 | Original Article

Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3⁺ Tregs in gastric cancer and its clinical significance

Authors: Yiting Geng, Hui Wang, Changqing Lu, Qing Li, Bin Xu, Jingting Jiang, Changping Wu

Published in: International Journal of Clinical Oncology | Issue 2/2015

Abstract

Objective

Immune escape plays an important role in tumor progression. In the present study, the expression of B7-H1, B7-H4 and Foxp3 involved in immune escape in gastric carcinoma was investigated and the corresponding clinical significance was evaluated.

Methods

Immunohistochemistry was used to detect the expression of B7-H1, B7-H4 and Foxp3 in 100 gastric cancer specimens, and 30 paracarcinoma tissues were used as the control.

Results

Both B7-H1 and B7-H4 showed high expression levels in gastric cancer tissues (65.0 and 71.0 %, respectively), and the expressions of B7-H1 and B7-H4 were positively correlated with the depth of tumor invasion, lymph node metastasis and American Joint Committee on Cancer (AJCC) stage (P < 0.05). The number of Foxp3⁺ Tregs was much higher in gastric cancer tissues than control tissues, which was positively correlated with lymph node metastasis (P < 0.05). Similarly, a positive correlation between B7-H1 or B7-H4 expression and the number of Foxp3⁺ Tregs was observed. The median overall survival rate of patients with high expression of B7-H1, B7-H4 and Foxp3 was significantly poorer than that of patients with low expression of these proteins (P < 0.05). Cox regression multivariate analysis confirmed that lymph node metastasis, AJCC stage, and B7-H1 and Foxp3 overexpression were independent prognostic factors.

Conclusion

B7-H1, B7-H4 and Foxp3 were overexpressed in gastric cancer tissues. B7-H1 and Foxp3 are negative prognostic factors for patients with gastric cancer.

Ferrone S, Whiteside TL (2007) Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16(4):755–774PubMedCrossRef

Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–477PubMedCrossRef

Pardoll DM (2002) Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2(4):227–238PubMedCrossRef

Chen J, Li G, Meng H et al (2012) Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 61(1):101–108PubMedCrossRef

Pan XC, Li L, Mao JJ et al (2013) Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. Oncol Lett 5(1):90–96PubMedCentralPubMed

Zhang L, Wu H, Lu D et al (2013) The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 32(46):5347–5358PubMedCentralPubMedCrossRef

Wang S, Chen L (2004) Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 6(8):759–766PubMedCrossRef

Zhu G, Augustine MM, Azuma T et al (2009) B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113(8):1759–1767PubMedCentralPubMedCrossRef

Ohigashi Y, Sho M, Yamada Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947–2953PubMedCrossRef

10.

Zheng X, Li XD, Wu CP et al (2012) Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie 35(11):700–705PubMedCrossRef

11.

Gadiot J, Hooijkaas AI, Kaiser AD et al (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192–2201PubMedCrossRef

12.

Wu C, Zhu Y, Jiang J et al (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19–24PubMedCrossRef

13.

Jiang J, Zhu Y, Wu C et al (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 59(11):1707–1714PubMedCrossRef

14.

Mailloux AW, Young MR (2010) Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol 30(5):435–447PubMedCentralPubMedCrossRef

15.

Hori S, Sakaguchi S (2004) Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 6(8):745–751PubMedCrossRef

16.

Gratz IK, Rosenblum MD, Abbas AK (2013) The life of regulatory T cells. Ann N Y Acad Sci 1283:8–12PubMedCrossRef

17.

Lu X, Liu J, Li H et al (2011) Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-beta1. J Surg Oncol 104(6):571–577PubMedCrossRef

18.

Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766–4772PubMed

19.

Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19(2):217–223PubMedCrossRef

20.

Association Japanese Gastric Cancer (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24CrossRef

21.

Hartgrink HH, Jansen EP, van Grieken NC et al (2009) Gastric cancer. Lancet 374(9688):477–490PubMedCrossRef

22.

Yeh JM, Kuntz KM, Ezzati M et al (2009) Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 124(1):157–166PubMedCentralPubMedCrossRef

23.

Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18 Pt 1):5271–5279PubMedCrossRef

24.

Brown JA, Dorfman DM, Ma FR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257–1266PubMedCrossRef

25.

Choi IH, Zhu G, Sica GL et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171(9):4650–4654PubMedCrossRef

26.

Kryczek I, Zou L, Rodriguez P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871–881PubMedCentralPubMedCrossRef

27.

Krambeck AE, Thompson RH, Dong H et al (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103(27):10391–10396PubMedCentralPubMedCrossRef

28.

Tringler B, Zhuo S, Pilkington G et al (2005) B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11(5):1842–1848PubMedCrossRef

29.

Tringler B, Liu W, Corral L et al (2006) B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100(1):44–52PubMedCrossRef

30.

Zang X, Thompson RH, Al-Ahmadie HA et al (2007) B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104(49):19458–19463PubMedCentralPubMedCrossRef

31.

Simon I, Liu Y, Krall KL et al (2007) Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106(1):112–118PubMedCrossRef

32.

Thompson RH, Zang X, Lohse CM et al (2008) Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68(15):6054–6058PubMedCentralPubMedCrossRef

33.

Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293–12297PubMedCentralPubMedCrossRef

34.

Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800PubMed

35.

Curiel TJ, Wei S, Dong H et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562–567PubMedCrossRef

36.

Prasad DV, Richards S, Mai XM et al (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18(6):863–873PubMedCrossRef

37.

Sica GL, Choi IH, Zhu G et al (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6):849–861PubMedCrossRef

38.

Zang X, Loke P, Kim J et al (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100(18):10388–10392PubMedCentralPubMedCrossRef

39.

Strauss L, Bergmann C, Szczepanski M et al (2007) A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13(15 Pt 1):4345–4354PubMedCrossRef

40.

Liu J, Zhang N, Li Q et al (2011) Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 6(4):e19495PubMedCentralPubMedCrossRef

41.

Loser K, Apelt J, Voskort M et al (2007) IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 179(1):365–371PubMedCrossRef

42.

Li Q, Chen J, Liu Y et al (2013) Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep 30(3):1215–1222PubMed

43.

Li H, Yu JP, Cao S et al (2007) CD4 +CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27(3):317–326PubMedCrossRef

44.

Bastid J, Cottalorda-Regairaz A, Alberici G et al (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32(14):1743–1751PubMedCrossRef

45.

Sun X, Wu Y, Gao W et al (2010) CD39/ENTPD1 expression by CD4 + Foxp3 + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139(3):1030–1040PubMedCentralPubMedCrossRef

Title: Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
Authors: Yiting Geng
Hui Wang
Changqing Lu
Qing Li
Bin Xu
Jingting Jiang
Changping Wu
Publication date: 01-04-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0701-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients

Comparison of diameter-axial-polar nephrometry and RENAL nephrometry score for treatment decision-making in patients with small renal mass

Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab

Opioid needs of terminally ill patients with gynecologic malignancies

Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations

Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index

Keynote webinar | Spotlight on antibody–drug conjugates in cancer